Back to Browse Journals » International Journal of Women's Health » Volume 1

Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy

Authors SA Kingsberg, S Kellogg, M Krychman

Published 20 August 2009 Volume 2009:1 Pages 105—111


Review by Single-blind

Peer reviewer comments 2

SA Kingsberg¹, S Kellogg², M Krychman³

1University Hospitals Case Medical Center, Case Western Reserve University Cleveland OH, USA; 2The Pelvic and Sexual Health Institute of Philadelphia, Drexel University College of Medicine, Philadelphia, USA; 3Southern California Center for Sexual Health and Survivorship Medicine, Newport Beach, CA, USA

Abstract: Vulvovaginal atrophy (VVA) and dryness are common symptoms of the decline in endogenous production of estrogen at menopause and often result in dyspareunia. Yet while 10% to 40% of women experience discomfort due to VVA, it is estimated that only 25% seek medical help. The main goals of treatment for vaginal atrophy are to improve symptoms and to restore vaginal and vulvar anatomic changes. Treatment choices for postmenopausal dyspareunia resulting from vulvovaginal atrophy will depend on the underlying etiology and might include individualized treatment. A number of forms of vaginal estrogen and manner of delivery are currently available to treat moderate to severe dyspareunia caused by VVA. They all have been shown to be effective and are often the preferred treatment due to the targeted efficacy for urogenital tissues while resulting in only minimal systemic absorption. Both healthcare professionals and patients often find it difficult to broach the subject of sexual problems associated with VVA. However, with minimal effort to initiate a conversation about these problems, healthcare providers can provide useful information to their postmenopausal patients in order to help them each choose the optimal treatment for their needs and symptoms.

Keywords: dyspareunia, postmenopausal vulvovaginal atrophy, vaginal estrogen therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Relaxin inhibits cardiac fibrosis and endothelial–mesenchymal transition via the Notch pathway

Zhou X, Chen X, Cai JJ, Chen LZ, Gong YS, Wang LX, Gao Z, Zhang HQ, Huang WJ, Zhou H

Drug Design, Development and Therapy 2015, 9:4599-4611

Published Date: 11 August 2015

Synthesis, antimicrobial and in vitro antitumor activities of a series of 1,2,3-thiadiazole and 1,2,3-selenadiazole derivatives

Mhaidat NM, Al-Smadi M, Al-Momani F, Alzoubi KH, Mansi I, Al-Balas Q

Drug Design, Development and Therapy 2015, 9:3645-3652

Published Date: 16 July 2015

Monocyte chemoattractant protein-1: a proinflammatory cytokine elevated in sarcopenic obesity

Lim JP, Leung BP, Ding YY, Tay L, Ismail NH, Yeo A, Yew S, Chong MS

Clinical Interventions in Aging 2015, 10:605-609

Published Date: 25 March 2015

Target-controlled infusion and population pharmacokinetics of landiolol hydrochloride in patients with peripheral arterial disease

Kunisawa T, Yamagishi A, Suno M, Nakade S, Honda N, Kurosawa A, Sugawara A, Tasaki Y, Iwasaki H

Therapeutics and Clinical Risk Management 2015, 11:107-114

Published Date: 17 January 2015

Synthesis, pharmacokinetics, and biological use of lysine-modified single-walled carbon nanotubes [Erratum]

Mulvey JJ, Feinberg EN, Alidori S, McDevitt MR, Heller DA, Scheinberg DA

International Journal of Nanomedicine 2015, 10:595-596

Published Date: 14 January 2015

Age-associated decrease in global DNA methylation in patients with major depression

Tseng PT, Lin PY, Lee Y, Hung CF, Lung FW, Chen CS, Chong MY

Neuropsychiatric Disease and Treatment 2014, 10:2105-2114

Published Date: 10 November 2014

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Magnetic Fe3O4 nanoparticles and chemotherapy agents interact synergistically to induce apoptosis in lymphoma cells

Hongmei Jing, Jing Wang, Ping Yang, et al

International Journal of Nanomedicine 2010, 5:999-1004

Published Date: 19 November 2010